Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

glyceryltrinitrate 500mcg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non–st-segment elevation acs (unstable angina [ua]/non–st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are c

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline tablets, usp are indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the antidepressant action of sertraline in hospitalized depressed patients has not been adequately st

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 250 mg - mycophenolate mofetil (mmf) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see clinical studies ( 14.1)] , heart [see clinical studies ( 14.2)] or liver transplants [see clinical studies ( 14.3)] , in combination with other immunosuppressants . allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. pregnancy exposure registry: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain information about the registry, visit www.mycophenolaterems.com or call 1-800-617-8191. risk summary: use of mycophenolate mofetil (mmf) during pregnancy is asso

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - diclofenac epolamine (unii: x5f8ekl9zg) (diclofenac - unii:144o8ql0l1) - diclofenac epolamine 180 mg - carefully consider the potential benefits and risks of flector® patch and other treatment options before deciding to use flector® patch. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (seewarnings ). flector® patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. flector® patch is contraindicated in patients with known hypersensitivity to diclofenac. flector® patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (seewarnings - anaphylactoid reactions , andprecautions - preexisting asthma ). flector® patch is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (seewarnings ). flector® patch should not be applied to non-intact or damaged skin r

United States - English - NLM (National Library of Medicine)

preferred pharmaceucitalc inc. - diclofenac epolamine (unii: x5f8ekl9zg) (diclofenac - unii:144o8ql0l1) - diclofenac epolamine 180 mg - flector® patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. flector patch is contraindicated in the following patients: risk summary published literature reports that use of nsaids, including flector patch, after 30 weeks' gestation increases the risk of premature closure of the fetal ductus arteriosus. data from observational studies regarding potential embryofetal risks of nsaid use, including diclofenac, in women in the first or second trimester of pregnancy are inconclusive. avoid use of nsaids, including flector patch, in pregnant women starting at 30 weeks of gestation (third trimester) (see clinical considerations and data) . in animal reproduction studies, diclofenac epolamine administered orally to pregnant rats and rabbits during the period of organogenesis produced embryotoxicity at approximately 3 and 7 times, respectively, the topical exposure from the maximum recommended human dose (mrhd) of flector patch. in rats, increased incidences of

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 5 mg - benazepril hydrochloride tablets usp are indicated for the treatment of hypertension. they may be used alone or in combination with thiazide diuretics. in using benazepril hydrochloride, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that benazepril hydrochloride does not have a similar risk (see warnings ). black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. benazepril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product or to any other ace inhibitor. benazepril hydrochloride tablets are also contraindicated in patients with a history of angioe

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ramelteon (unii: 901as54i69) (ramelteon - unii:901as54i69) - ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset. the clinical trials performed in support of efficacy were up to six months in duration. the final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see clinical studies (14)] . patients who develop angioedema after treatment with ramelteon should not be rechallenged with the drug. patients should not take ramelteon in conjunction with fluvoxamine [see drug interactions (7)] . risk summary available data from postmarketing reports with ramelteon use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, ramelteon produced evidence of developmental toxicity, including teratogenic effects, in rats at doses greater than

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - decoquinate -

Israel - English - Ministry of Health

cts chemical industries ltd, israel - nifedipine - tablets prolonged release - nifedipine 60 mg - nifedipine - nifedipine - chronic stable angina, hypertension.